Capricor reports Q3 net loss $12.6M; starts BLA for deramiocel, signs $715M European deal

CAPRICOR THERAPEUTICS, INC.

2024-Q3 EPS reported -$1.04 revenue$11,139,956

Q3 net loss $12.6M ($0.38/sh) vs $6.4M ($0.25/sh); revenue $2.3M vs $6.2M.
Began rolling BLA submission for deramiocel (DMD cardiomyopathy) Oct 2024; full submission expected year-end; PDUFA H2 2025.
Signed binding term sheet with Nippon Shinyaku for Europe: $20M upfront, up to $715M milestones plus double-digit revenue share.
Public offering net proceeds ~$80.8M; cash $85M at Sep 30; runway into 2027.
Nippon Shinyaku purchased ~$15M of CAPR stock at 20% premium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.